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The Yersiniabactin-Associated ATP Binding Cassette Proteins YbtP
and YbtQ Enhance Escherichia coli Fitness during High-Titer Cystitis
Eun-Ik Koh, Chia S. Hung, Jeffrey P. Henderson
Center for Women’s Infectious Diseases Research, Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis,
Missouri, USA
The Yersinia high-pathogenicity island (HPI) is common to multiple virulence strategies used by Escherichia coli strains associ-
ated with urinary tract infection (UTI). Among the genes in this island are ybtP and ybtQ, encoding distinctive ATP binding cas-
sette (ABC) proteins associated with iron(III)-yersiniabactin import in Yersinia pestis. In this study, we compared the impact of
ybtPQ on a model E. coli cystitis strain during in vitro culture and experimental murine infections. A ybtPQ-null mutant exhib-
ited no growth defect under standard culture conditions, consistent with nonessentiality in this background. A growth defect
phenotype was observed and genetically complemented in vitro during iron(III)-yersiniabactin-dependent growth. Following
inoculation into the bladders of C3H/HEN and C3H/HeOuJ mice, this strain exhibited a profound, 106-fold competitive infec-
tion defect in the subgroup of mice that progressed to high-titer bladder infections. These results identify a virulence role for
YbtPQ in the highly inflammatory microenvironment characteristic of high-titer cystitis. The profound competitive defect may
relate to the apparent selection of YersiniaHPI-positive E. coli in uncomplicated clinical UTIs.
Urinary tract infection (UTI) is one of the most common bac-terial infections, affecting nearly 9 million individuals every
year in the United States (1). Uropathogenic Escherichia coli
(UPEC) is responsible for over 80% of all community-acquired
UTI cases and in some patients progresses from a localized blad-
der infection to an infection of the kidneys and bloodstream (2, 3).
Over 50% of women acquire a UTI over their lifetimes, with 30%
suffering from recurrent UTIs (4, 5). Uncomplicated UTIs appear
to follow an ascending route of infection in which the bladder is
exposed to a polymicrobial inoculum of intestinal bacteria that
colonize the vaginal vestibule and urethra (6–10). This early col-
onization event may precede patients’ visits to physicians by sev-
eral days. Our understanding of the molecular mechanisms that
UPEC uses to emerge from this early inoculum and dominate the
urinary microbiome at the time of clinical UTI diagnosis remains
incomplete.
When an uncomplicated UTI patient’s rectal and urinary E.
coli strains are compared, the urinary strain is more likely to carry
the 30-kb Yersinia high-pathogenicity island (HPI) (11). The Yer-
sinia HPI is nearly ubiquitous among model uropathogenic E. coli
strains, is associated with fluoroquinolone resistance when pres-
ent in combination with the aerobactin siderophore system, and is
typically present in over 70% of clinical urinary isolates (3, 11, 12).
The Yersinia HPI encodes the yersiniabactin (Ybt) siderophore
system, including yersiniabactin biosynthetic enzymes, in addi-
tion to outer and inner membrane transporters associated with
metal-yersiniabactin complex import (13–16). Yersiniabactin is
one of three genetically nonconserved E. coli siderophore types
(yersiniabactin, salmochelin, and aerobactin) that may be ex-
pressed in addition to enterobactin, the conserved E. coli sidero-
phore (3, 11, 12). The Yersinia HPI is central to multiple E. coli
urovirulence strategies, raising the possibility that it is functionally
distinct from other siderophore systems (12). In uropathogenic E.
coli, the yersiniabactin system has been appreciated to facilitate
importer-independent copper and reactive oxygen species resis-
tance (17, 18). Furthermore, in Yersinia pestis, the yersiniabactin
system is linked to zinc import (19). E. coli virulence may be en-
hanced in strains that use multiple siderophore types, including
yersiniabactin, to overcome the metal ion limitation characteristic
of nutritional immunity (20, 21). These observations raise the
question of whether importer-dependent functions associated
with the Yersinia HPI, such as metal ion acquisition, are patho-
physiologically important during a UTI (14, 16).
Seminal studies with Yersinia pestis identified several proteins
that are specifically necessary for iron(III)-yersiniabactin-depen-
dent growth (14, 15). Within the Yersinia HPI, the inner mem-
brane transporter genes (ybtP and ybtQ) are present in an operon
that is separate from the outer membrane transporter gene (de-
noted psn in Y. pestis and fyuA in other bacteria) operon. Both
operons are regulated in part by the AraC-like transcription factor
YbtA (see Fig. S1 in the supplemental material) (13, 14, 22, 23).
Typical of most outer membrane siderophore transporters, FyuA
uses the TonB complex to import its cognate iron(III)-sidero-
phore [Fe(III)-yersiniabactin] complex into the periplasmic space
(15, 16, 24). Unlike most siderophore-associated inner membrane
transporters, ybtP and ybtQ are overlapping genes (overlapping by
40 nucleotides); they each encode half of an inner membrane
ATP-binding cassette (ABC) transporter, and they each have un-
usual amino-terminal membrane-spanning domains and car-
boxy-terminal ATPases (14). It is unclear whether these unusual
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structural features correspond to atypical or complex functional-
ity. While siderophore-associated ABC transporters are typically
implicated in iron(III)-siderophore transport, some members of
this family possess additional signaling roles (25). Metabolomic
comparisons also raise the possibility that YbtP and YbtQ may
exert functions distinct from iron(III)-yersiniabactin utilization
in UPEC (26).
The overall expression of the yersiniabactin system can be in-
ferred by evidence of yersiniabactin biosynthesis as well as sero-
logical and transcriptional evidence of ybtP, ybtQ, and fyuA ex-
pression during mouse and human cystitis (17, 27–29). Beyond
UTIs, ybtPQ mutants of Yersinia pestis and Klebsiella pneumoniae
exhibit diminished virulence in mouse models of bubonic plague
and pneumonia, respectively (14, 30). ybtP and ybtQ homologues
in Pseudomonas aeruginosa and Mycobacterium tuberculosis also
affected virulence in a burned mouse model of sepsis and a mouse
aerosol infection model (31, 32). The broad spectrum of patho-
gens associated with these distinctive bacterial proteins makes
their associated functions an intriguing target for future viru-
lence-associated therapies.
In this study, we sought to determine whether YbtP and YbtQ
affect urinary tract infection pathogenesis. Using a combined bac-
teriologic and liquid chromatography-mass spectrometry ap-
proach, we found that YbtPQ is necessary for iron(III)-Ybt-de-
pendent growth but not Ybt synthesis in a UPEC strain. We next
compared isogenic wild-type and ybtPQ mutant strains in an ex-
perimental murine cystitis model using C3H/HeN and C3H/
HeOuJ mice, which are known to develop distinctive high-titer,
persistent infections with UPEC. A uropathogenic E. coli strain
lacking ybtPQ exhibited a profound competitive fitness defect
during high-titer infections but not under low-iron liquid culture
conditions. These results are consistent with an important role for
YbtP and YbtQ in inflamed bladder microenvironments during
UTI pathogenesis.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. Uropathogenic E.
coli isolate UTI89, the genome of which encodes the enterobactin, salmo-
chelin, and yersiniabactin siderophore systems, was used in this study (33,
34). Strains were grown in lysogeny broth (LB) agar (Becton, Dickson and
Company) or M63 minimal medium supplemented with 0.2% (vol/vol)
glycerol and 10 mg ml1 niacin (Sigma) with antibiotics as appropriate
(11). Ampicillin (100 g ml1; GoldBio) and kanamycin (50 g ml1;
GoldBio) were used for strain selection. The UTI89 mutant strains used in
this study are listed in Table 1. In-frame deletions in the UTI89 genome
were made using the bacteriophage lambda Red recombinase method
with pKD4 or pKD13 as the template (35). PCR with flanking primers was
used to confirm the deletions. Antibiotic resistance insertions were re-
moved by transforming strains with pCP20 expressing FLP recombinase.
A YbtPQ-expressing plasmid was constructed with the pTrc99a vector
(36) using standard PCR and recombination techniques.
Yersiniabactin and 13C-yersiniabactin preparation. Apo-Ybt was
generated from UTI89 entB grown in M63 minimal medium supple-
mented with 0.2% (vol/vol) glycerol and 10 mg ml1 niacin (Sigma) as
previously described (17). 13C-Ybt was generated by growing UTI89fur
in medium supplemented 13C-labeled glycerol as previously described
(17). Iron(III)-Ybt complexes were produced by adding iron(III) chloride
(Sigma) to apo-Ybt. Iron(III)-Ybt was applied to a methanol-conditioned
C18 silica column (Sigma) and eluted with 80% methanol as previously
described (16). The eluates were lyophilized overnight. Dried samples
were resuspended in deionized water and purified through high-perfor-
mance liquid chromatography (HPLC) using a C18 silica column (Partisil;
Whatman). Iron(III)-Ybt-containing fractions were collected, dried us-
ing a lyophilizer, and resuspended in deionized water. Stock iron(III)-Ybt
quantification was carried out using the previously described extinction
coefficient (16). Sample iron(III)-Ybt levels were quantified in multiple
reaction monitoring mode using known collision-induced dissociation
fragmentations and 13C-labeled Fe(III)-Ybt internal standards.
Fe(III)-Ybt-dependent growth. After overnight growth in M63 min-
imal medium, strains were normalized for the starting optical density at
600 nm (OD600) in M63 minimal medium with 2 mM ethylenediamine-
N,N=-bis(2-hydroxyphenylacetic acid) (EDDHA; Complete Green Com-
pany). HPLC-purified Fe(III)-Ybt (1 M) was added to the strains, and
the strains were grown for 18 h in 37°C with shaking, as previously de-
scribed (16). Bacterial growth was measured using OD600 readings.
Mouse infections. The bacteria used for infection were prepared as
previously described (37). Six- to 7-week-old female C3H/HeN mice
(Harlan) and C3H/HeOuJ mice (The Jackson Laboratory) were transure-
thrally infected with a 50-l suspension containing 1 107 CFU of UTI89
or UTI89 ybtPQ in phosphate-buffered saline (PBS) while they were
under 4% isoflurane anesthesia (37, 38). All animal experiments received
prior review and approval of the Animal Studies Committee at Washing-
ton University School of Medicine. For competitive infections, the mice
were infected with a 50-l combined suspension containing 5 106 CFU
each of UTI89 and UTI89ybtPQ::Kanr in PBS while they were under 4%
isoflurane anesthesia. At the time points indicated below, they mice were
sacrificed by cervical dislocation while they were under isoflurane anes-
thesia, and their bladders and kidneys were aseptically removed. The or-
gans were homogenized in PBS and were then serially diluted, and a total
of 50l of each dilution was spotted onto LB agar plates and LB agar plates
with 50 g/ml kanamycin where appropriate. Competitive indices (CIs)






KanrCFU in), where UTI89CFU out is the number of CFU of UTI89 recov-
ered, UTI89CFU in is the number of CFU of UTI89 inoculated, UTI89
ybtPQ::KanrCFU out is the number of CFU of UTI89ybtPQ::Kan
r recov-
ered, and UTI89 ybtPQ::KanrCFU in is the number of CFU of UTI89
ybtPQ::Kanr inoculated (39).
Bladder IBCs. Bladders were aseptically removed at 6 h postinfection
to count the number of intracellular bacterial communities (IBCs). Har-
vested bladders were bisected, splayed on silicone plates, and fixed in 2%
paraformaldehyde. IBCs were quantified by LacZ staining of whole blad-
ders as previously described (40).
In vitro cogrowth experiments. The bacteria used for cogrowth ex-
periments were prepared in the same way that the bacteria were prepared
for infection of mouse described above. Five microliters of a combined
suspension containing 5 106 CFU each of UTI89 and UTI89 ybtPQ::
Kanr in PBS was inoculated into 5 ml M63 minimal medium, and the
bacteria were grown at 37°C statically or with shaking, as indicated below.
At the time points indicated below, the cultures were removed and serially
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diluted, and a total of 50 l of each dilution was spotted onto LB agar
plates and LB agar plates with 50 g/ml kanamycin where appropriate.
Statistical analysis. Student’s t test was used to compare yersiniabac-
tin biosynthesis levels between pairs of strains. A two-tailed Mann-Whit-
ney U test was used to compare bladder and kidney colonization levels and
IBC counts between UTI89 and UTI89 ybtPQ. The Wilcoxon signed-
rank test was used to compare the log of the competitive indices to a
theoretical median of 0. Statistics and graphs were generated using Graph-
Pad Prism (version 5) software (GraphPad Software).
RESULTS
ybtPQ deletion does not affect growth under iron(III)-Ybt-
independent conditions. To investigate the role of YbtPQ in uro-
pathogenic E. coli growth, we first measured the growth of the
model UPEC strain UTI89 in nutrient-rich LB medium as well as
M63 minimal medium. The growth of UTI89 ybtPQ was indis-
tinguishable from that of wild-type strain UTI89 in both media
(Fig. 1A and B). Addition of the ferric ion chelator EDDHA (2 mM),
which sequesters Fe(III) and renders it poorly accessible to sidero-
phores, to M63 minimal medium prior to inoculation diminished the
growth of both strains to a similar degree. Addition of 1M purified
Fe(III)-Ybt reversed the EDDHA-mediated inhibition of wild-type
strain UTI89 but not that of UTI89ybtPQ. Genetic complementa-
tion of UTI89 ybtPQ with ybtPQ expressed on a plasmid restored
growth to wild-type levels under this EDDHA/Fe(III)-Ybt condition
(Fig. 1C and D). Insertion of an empty vector did not restore UTI89
ybtPQ growth to wild-type levels under this EDDHA/Fe(III)-Ybt
condition (data not shown). These results are consistent with ybtP
and ybtQ being nonessential genes that permit Fe(III)-Ybt to be used
as an iron source by UPEC.
ybtPQ is not required for yersiniabactin synthesis in UPEC.
ybtPQ shares an operon with the yersiniabactin biosynthetic gene
ybtS (see Fig. S1 in the supplemental material). To determine
whether ybtPQ deletion exerts pleiotropic effects upon Ybt syn-
thesis in UPEC, we compared the levels of Ybt secretion between
wild-type strain UTI89 and strains UTI89 ybtPQ::Kanr (Fig. 2)
and UTI89 ybtPQ (see Fig. S2 in the supplemental material) in
M63 minimal medium. Yersiniabactin production by UTI89
ybtS was undetectable, while that by UTI89 ybtPQ::Kanr was
comparable to that by wild-type strain UTI89. UTI89 ybtPQ::
Kanr complemented with ybtPQ expressed on a plasmid showed a
small but significant increase in Ybt synthesis compared to that of
UTI89. UTI89 ybtPQ also showed no difference in Ybt biosyn-
thesis compared to that of wild-type strain UTI89. These results
show that yersiniabactin biosynthesis is preserved in UTI89 ybtPQ
deletion mutants, similar to previous results seen in studies withY.
pestis and Yersinia enterocolitica (14, 23). These results also sup-
FIG 1 YbtPQ is required for Fe(III)-Ybt-dependent growth in UPEC. (A and B) The growth of UTI89, UTI89 ybtPQ, and UTI89 ybtPQ/pybtPQ was
indistinguishable in nutrient-rich LB medium (A) and nutrient-limiting M63 minimal medium supplemented with 0.2% (vol/vol) glycerol and 10 mg
ml1 niacin (B). (C) In M63 minimal medium chelated with 2 mM EDDHA, all strains show decreased growth. (D) This growth defect was rescued for
UTI89 and UTI89 ybtPQ/pybtPQ upon addition of exogenous 1 M Fe(III)-Ybt to the chelated medium. Results are shown as means  SDs (n  3).
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port a function for ybtPQ in UPEC that is distinct from yersini-
abactin biosynthesis.
Individual infections by the wild type and ybtPQmutants in
C3H/HeN mice. We hypothesized that the loss of ybtPQ would
affect in vivo fitness during urinary tract infection. We tested this
in C3H/HeN mice (homozygous for the retinal degeneration allele
Pde6brd1), where a 107-CFU E. coli transurethral inoculum causes
an infection involving epithelial cell invasion followed by a bifur-
cation to high and low numbers of CFU that are evident as soon as
3 days postinfection (dpi) (38). By 4 weeks postinfection, the mice
with high numbers of CFU exhibit high-titer (104 CFU per or-
gan) bladder colonization that is characterized by urothelial hy-
perplasia and high levels of inflammation (37, 38, 41). We first
conducted single-strain inoculations with UTI89 or UTI89
ybtPQ. The bladder and kidneys were harvested at 7 and 14 days
postinfection, and the numbers of CFU of both strains were de-
termined (Fig. 3). As was observed previously (38), mice infected
with wild-type strain UTI89 exhibited a bimodal distribution of
the numbers of CFU in the bladder at 7 and 14 dpi, with one group
exhibiting greater than 105 CFU per bladder and the other group
exhibiting less than 104 CFU per bladder. Mice infected with
UTI89 ybtPQ showed no statistically significant differences in
the numbers of CFU in either the bladder or kidneys compared
with those in the bladder or kidneys of mice infected with wild-
type strain UTI89 (Fig. 3A and B). These results indicate that
YbtPQ is not required for the development of acute and persistent
high-titer colonization in infections with a single strain.
Bladder IBC assessment. To further assess the role of YbtPQ
in acute cystitis, we quantified the formation of bladder intracel-
lular bacterial communities (IBCs). IBCs are biofilm-like aggre-
gations of UPEC that have invaded and subsequently replicated in
the cytoplasm of bladder superficial umbrella cells (42, 43). Dur-
ing acute bladder infection, IBCs have been observed at up to 24 h
postinoculation (27, 43). C3H/HeN mice were infected with 107
CFU of UTI89 ybtPQ or wild-type strain UTI89. The bladders
were harvested at 6 h postinfection, and IBCs were quantified by
LacZ staining (see Fig. S3 in the supplemental material). IBCs
were observed during UTI89 ybtPQ infections, and the number
of IBCs per bladder was not significantly different from the num-
ber observed during wild-type strain UTI89 infections. These re-
sults indicate that YbtPQ is not required for IBC development.
Competitive infections and in vitro cogrowth with the wild
type and the ybtPQ mutant. Previous observations suggest that
uncomplicated UTIs originate with the polymicrobial inoculation
of the urinary tract and that patient rectal E. coli strains with the
Yersinia high-pathogenicity island are preferentially recovered
from patient urine once the infections become symptomatic (10,
11). To determine if the loss of ybtPQ function would affect fitness
during mixed inoculation with a wild-type strain with an intact
ybtPQ, we measured the levels of wild-type strain UTI89 and
UTI89ybtPQ::Kanr in competitive infections. We infected C3H/
HeN mice with a total inoculum of 107 CFU consisting of a 1:1
ratio of the wild type and mutant UTI89. In both the bladder and
kidneys, we saw a significant (P	 0.05) increase in mean compet-
itive index (CI) values over time, demonstrating that wild-type
strain UTI89 outcompetes the mutant strain (Fig. 4A and B). By 3
days postinfection, a markedly bimodal CI distribution became
apparent in the bladders, with one group demonstrating CIs of
greater than 104 (a 10,000-fold increase in wild-type selection) and
the other demonstrating CIs of less than 101 (a 10-fold increase in
wild-type selection). This separation was widened by 7 and 14 days
postinfection. A similar progression toward a bimodal CI distri-
bution was observed in the kidneys. Neither a high CI nor a bi-
modal distribution was observed in a competitive inoculation of
wild-type strain UTI89 and UTI89 ybtPQ::Kanr into M63 mini-
mal medium under static or shaking conditions at 37°C (Fig. 4C
FIG 2 YbtPQ is not required for Ybt synthesis in UPEC. Yersiniabactin pro-
duction was determined from the culture supernatants of UTI89 strains using
quantitative liquid chromatography-tandem mass spectrometry methods.
While salicylate synthesis-deficient strain UTI89 ybtS showed a decreased
level of Ybt production, the level of Ybt production by strain UTI89 ybtPQ::
Kanr showed no difference from that by the wild type. UTI89 ybtPQ::Kanr/
pybtPQ showed an increased level of Ybt synthesis compared to that of the wild
type. Results are shown as means SDs (n 3). **,P	 0.005; ***,P	 0.0005;
NS, not significant.
FIG 3 In vivo single-strain infections in a C3H/HeN mouse background. Bacterial titers at 7 days and 14 days following inoculation with 107 CFU UTI89 or
UTI89 ybtPQ in the bladders (A) and kidneys (B) from C3H/HeN mice are shown. Statistical significance was assessed using the two-tailed Mann-Whitney U
test. The numbers above the bars indicate the mean values.
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and D). UTI89 ybtPQ::Kanr showed only a small competitive
defect against the wild-type strain under both static and shaking
conditions near 7 days postinoculation. Together, these results
suggest that UPEC strains lacking YbtPQ are at a marked compet-
itive disadvantage in the distinctive host environment of the
mouse cystitis model.
The unusual bimodal CI distribution observed here resembles
the bimodal distribution of the numbers of CFU in the bladder
seen in this C3H/HeN mouse model of cystitis (38) (Fig. 3). To
determine whether the CI distribution is related to infection se-
verity, we compared the CI values with the total number of CFU
(Fig. 5A and B). The group with high CIs corresponded to mice
with high titers in the bladder, while the group with low CIs cor-
responded to mice with low titers in the bladder. The CI values
within the high-titer group progressively increased over the
course of 3-, 7-, and 14-day infections until they were near the
maximum resolvable CI limit (on the basis of the numbers of
CFU). A similar relationship was observed in the kidneys, al-
though the numbers of CFU were more evenly distributed and CI
values appeared to approach the maximum resolvable limit for all
values of the numbers of CFU. Together, these results suggest that
the persistent high-titer but not low-titer bladder infection envi-
ronment strongly favors UPEC strains with an intact yersiniabac-
tin import system. This may relate to the apparent selection of E.
coli strains with the Yersinia HPI in UTI patients (11).
Competitive infections by the wild type and ybtPQ mutants
inC3H/HeOuJmice.To determine whether the loss of YbtPQ has
similar effects during infection in other mouse backgrounds, we
competitively inoculated C3H/HeOuJ mice (homozygous for the
retinal degeneration allele Pde6brd1) with wild-type strain UTI89
and UTI89 ybtPQ::Kanr as described above for C3H/HeN mice.
C3H/HeOuJ mice have previously been shown to be highly sus-
ceptible to persistent bladder and kidney infections caused by
UPEC (38, 44). Similar to the results seen in C3H/HeN mice, we
saw a significant increase (P	 0.05) in mean CI values over time
in both the bladder (Fig. 6A) and the kidneys (see Fig. S4A in the
supplemental material). When we compared CI values with the
total number of CFU, we again observed that the group with high
CIs corresponded to mice with high titers and the group with low
CIs corresponded to mice with low titers in both the bladder (Fig.
6B) and the kidneys (see Fig. S4B), similar to the findings for
C3H/HeN mice.
We also conducted single-strain inoculations with UTI89 or
UTI89 ybtPQ. Similar to the results seen in C3H/HeN mice,
mice infected with wild-type strain UTI89 exhibited a bimodal
distribution of the numbers of CFU detected in the bladder. In
mice infected with UTI89 ybtPQ, by 14 days postinfection there
was a significant decrease in the mean number of CFU per bladder
compared to the number seen in mice infected with wild-type
strain UTI89 (see Fig. S5A in the supplemental material). Even
though significantly lower numbers of CFU were observed in the
kidneys at 3 days postinfection with UTI89ybtPQ, there were no
FIG 4 In vivo competitive infection in C3H/HeN mice and in vitro coculture
growth. UTI89 showed a significant competitive advantage over UTI89
ybtPQ::Kanr during in vivo competitive infections compared to that seen
during coculture growth in vitro. UTI89 and UTI89ybtPQ::Kanr were mixed
1:1 to a total of 107 CFU prior to coinfection and coculture. (A and B) Com-
petitive infections were performed in C3H/HeN mice, and bacterial titers in
the bladders (A) and kidneys (B) were determined. (C and D) UTI89 strains
were cocultured in M63 minimal medium under shaking (C) and static (D)
conditions. Each symbol represents a datum from an individual mouse or
culture. Statistical significance was assessed using the Wilcoxon signed-rank
test, with a log10 CI of 0 (dotted line) being used as the theoretical median.
Numbers at the top indicate median values. *, P 	 0.05. The bars indicate
mean values.
FIG 5 In vivo competitive infections in C3H/HeN mice show a correlation
with bacterial levels. Presentation of the competitive index values against the
total bacterial titers from the bladders (A) and kidneys (B) of C3H/HeN mice
revealed that mice with high competitive indices had high bacterial titers in
each organ, while mice with low competitive indices had low bacterial burdens
in each organ.
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statistically significant differences in the numbers of CFU per kid-
ney at later time points (see Fig. S5B in the supplemental mate-
rial). These results suggest that UPEC strains with an intact yers-
iniabactin import system have greater fitness during persistent
high-titer bladder infections.
DISCUSSION
In this study, we show that the UPEC genome-encoded ATP-
binding cassette transporters YbtP and YbtQ promote bacterial
fitness during urinary tract infections. YbtPQ most profoundly
affected fitness in the highly inflammatory infection environment
of high-titer mouse cystitis. While wild-type UPEC exhibited up
to a 106-fold greater survival than the coinoculated ybtPQ deletion
mutants in murine infections, no such competitive defect was
noted during in vitro cultures. This report is the first to describe a
role for YbtPQ during E. coli urinary tract infection, in which
ybtPQ causes a defect that is among the strongest competitive
defects reported to be caused by a nonconserved, nonessential
gene during experimental cystitis. It is notable that this phenotype
is evident in strain UTI89, where in vitro iron uptake by yersini-
abactin is redundant with that of the enterobactin and salmoche-
lin siderophore systems. Together, these data suggest that YbtPQ
contributes distinctive functions that facilitate the urovirulence of
E. coli carrying the Yersinia high-pathogenicity island.
Previous work has found that in patients with intestinal colo-
nization by multiple E. coli strains, strains possessing the Yersinia
HPI are preferentially isolated from their urine at the time of UTI
diagnosis (11). Here, the profound competitive disadvantage for
YbtPQ-null UPEC strains during high-titer infections, but not in
vitro culture suggests a similar advantage for Yersinia HPI-ex-
pressing E. coli strains in the polymicrobial inoculum preceding
uncomplicated UTIs in humans. Features of the high-titer infec-
tion state in C3H/HeN and C3H/HeOuJ mice suggest aspects of
the host response that may select against YbtPQ-null UPEC. In
these infections, up to 20% of bladder UPEC isolates are intracel-
lular and exist within urothelial cells, macrophages, and neutro-
phils. The high-titer infection state is also characterized by a ro-
bust inflammatory response, which was shown to be required for
the development of chronic cystitis (38, 45). If these aspects of the
host response do select against YbtPQ-null UPEC, a virulence
defect during single-strain infections may be more difficult to re-
solve if the mutant strain elicits an inflammatory response less
vigorous than that which is present during a mixed infection with
wild-type UPEC. If so, a potentially greater inflammatory re-
sponse during a mixed infection may favor wild-type UPEC sur-
vival. These inflammatory responses may resemble those present
during the 2 to 3 days of the preclinical UTI that predate the
patient’s decision to seek treatment for UTI symptoms (5). The
current study thus raises the possibility that the yersiniabactin
import pathway equips UPEC to better overcome barriers to
growth imposed by inflammatory microenvironments in the in-
fected host.
With the notable exception of Y. pestis YbtP and Salmonella
enterica serovar Typhimurium IroC (14, 46), experimental infec-
tion studies have tended to focus upon the TonB-dependent outer
membrane siderophore transporters, rather than siderophore-as-
sociated inner membrane ABC protein components. A recent
study using a fyuA-deficient UPEC strain found that it had a com-
petitive defect in the bladder weaker than that observed for the
ybtPQ-deficient UPEC strain in the present study. In contrast, the
defect in infections with a single strain was somewhat more pro-
nounced for fyuA mutants than ybtPQ mutants (29, 47–50). A
previous study using a tonB-deficient UPEC strain yielded results
similar to those obtained with the fyuA mutant (51). The notable
differences between fyuA and ybtPQ mutants are interesting and
may derive from different strain backgrounds or distinctive fea-
tures of the C3H background mice used in this study. It is possible
that the robust inflammation in C3H mice increases UPEC outer
membrane permeability (through antimicrobial peptides), mak-
ing outer membrane transporters relatively less critical for metal-
yersiniabactin import (52–54). Lastly, the marked competitive ad-
vantage observed with YbtPQ may derive from additional
virulence functions that are not directly related to yersiniabactin
import. For example, Lv and Henderson have shown that a UTI89
ybtPmutant exhibits a significant change in cellular cysteine levels
compared to those found in an isogenic fyuA mutant (26). More
direct experimental functional comparisons of outer and inner
membrane siderophore import proteins will be necessary to un-
derstand how functionally distinct these proteins may be.
Structurally diverse ABC cassette transporters such as YbtPQ
FIG 6 In vivo competitive infection with C3H/HeOuJ mice. UTI89 showed a significant competitive advantage over UTI89 ybtPQ::Kanr during in vivo
competitive infections in C3H/HeOuJ mice. UTI89 and UTI89 ybtPQ::Kanr were mixed 1:1 to total of 107 CFU prior to coinfection. (A) Competitive indices
were calculated from the bacterial titers collected from the bladders. (B) Competitive index values against total bacterial titers from the bladders are presented.
Each symbol represents a datum from an individual mouse. Statistical significance was assessed using the Wilcoxon signed-rank test, with a log10 CI of 0 (dotted
line) being the theoretical median. Numbers at the top indicate median values. *, P	 0.05. The bars indicate mean values.
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have been the subject of extensive pharmacologic study in both
eukaryotes and prokaryotes, making this an appealing class of tar-
gets for new anti-infectives (55, 56). Structural differences in ABC
transporters between humans and bacteria may enable antibiotics
with specificity to be identified. Numerous functions of the bac-
terial ATP-binding cassette transporter superfamily have been de-
scribed in both Gram-positive and Gram-negative pathogens (25,
55–57). Further investigation of the mechanisms of action of ABC
transporters will provide insight into their role during pathogen-
esis as well as allow the development of countermeasures targeting
these transporters.
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